Celestica's CCS segment is rapidly gaining share among hyperscalers, driven by next-gen product launches and strong positioning in AI/ML networking.

Teradata remains a deep value play after disappointing earnings, but recent cash flow strength and favorable valuation metrics keep me cautiously optimistic.

Dear W.D.W.: It is completely understandable to be concerned about a PSA level of 18 ng/mL, but you and your urologist have, ...

In a market where top cryptos like Bitcoin and Ethereum are out of reach for small-budget investors, low-cost, high-upside ...

Biopharma and CROs Gain Direct Access to PhaseV's Leading Platform to Accelerate Clinical Trials and Cut Costs by Up to 50% ...

One tool to help people remember ... In 2020, the result was 11.8 ng/mL, and it has risen to 17-18 ng/mL, where it has stayed for the past year. Since July 2024, I have been taking 10 mg of alfuzosin ...

Year-Over-Year Growth in First-Half Contracts Highlights Accelerating Adoption of AI-Powered Security and Strong Market ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Cloudastructure, Inc. (Nasdaq: CSAI) ("we," "us," "our," "Cloudastructure" or the "Company"), a recognized leader in AI Surveillance and Remote Guarding ...

Certain urine biomarkers may noninvasively assess kidney health in patients with diabetic kidney disease and help identify ...